Making sense of glucose sensors in end-stage kidney disease: A review
Diabetes mellitus remains the leading cause of end-stage kidney disease worldwide. Inadequate glucose monitoring has been identified as one of the gaps in care for hemodialysis patients with diabetes, and lack of reliable methods to assess glycemia has contributed to uncertainty regarding the benefi...
Main Authors: | Mark E. Williams, Devin Steenkamp, Howard Wolpert |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Clinical Diabetes and Healthcare |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcdhc.2022.1025328/full |
Similar Items
-
Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: A pilot study
by: Sua Lee, et al.
Published: (2023-04-01) -
Targeting predialysis glucose up to 180 mg/dl reduces glycemic variability in end stage diabetic nephropathy
by: Nikita Shah, et al.
Published: (2022-01-01) -
Neuromuscular Electrical Stimulation during Hemodialysis Suppresses Postprandial Hyperglycemia in Patients with End-Stage Diabetic Kidney Disease: A Crossover Controlled Trial
by: Tomoki Tsurumi, et al.
Published: (2022-10-01) -
What Nephrologists Should Know about the Use of Continuous Glucose Monitoring in Type 2 Diabetes Mellitus Patients on Chronic Hemodialysis
by: Faiza Lamine, et al.
Published: (2022-08-01) -
Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?
by: Yifei Mo, et al.
Published: (2024-01-01)